The possibilities of neuroblastoma therapeutics based on targeting of MYCN have advanced recently, notably with the demonstration that small molecule inhibitors targeting Aurora kinase A such as Alisertib (MLN8237) can trigger depletion of MYCN protein in NB cell‐lines and in the murine model of NB, leading to NB growth inhibition and tumour regression. The gene discussed is MYCN; the disease is neoplasm.